References
- Kane J, Honigfeld G, Singer J et al. Clozaril Collaborative Study Group: Clozapine for the treatment-resistant schizophrenic: a double-blind comparison with chlorpromazine. Airh. Gen. Psychiatry45, 785–796 (1988).
- Marder SR, Meibach RC. Risperidone in the treatment of schizophrenia. Am. Psychiatry 151,825–835 (1994).
- Peuskens J. Risperidone in the treatment of patients with chronic schizophrenia: a multinational, multi-centre, double-blind, parallel group study versus haloperidol. Br. Psychiatry166,712— 726 (1995).
- Arvanitis LA, Miller BG and the Seroquel Trial 13 Study Group. Multiple fixed doses of `seroquel' (quetiapine) in patients with acute exacerbation of schizophrenia: a comparison with haloperidol and placebo. Biol. Psychiatry 42,233–246 (1997).
- Tollefson GD, Beasley CM, Tran PV et al. Olanzapine versus haloperidol in the treatment of schizophrenia and schizoaffective and schizophreniform disorders: results of an international collaborative trial. Am. j Psychiatry 154, 457–465 (1997).
- Buchanan RW, Breier A, Kirkpatrick B et al Positive and negative symptom response to clozapine in schizophrenic patients with and without the deficit syndrome. A117. I Psychiatry155, 751–760 (1998).
- Breier A, Hamilton SH. Comparative efficacy of olanzapine and haloperidol for patients with treatment-resistant schizophrenia. Biol. Psychiatry45, 403–411 (1999).
- Leucht S, Pitschel-Walz G, Abraham D et al Efficacy and extrapyramidal side effects of the new antipsychotics olanzapine, quetiapine, risperidone and sertindole compared to conventional antipsychotics and placebo. A meta-analysis of randomized controlled trials. Schiz. Res. 35, 51–68 (1999).
- •Provides an overview of the side effects of PGA and SGA agents.
- Lee MA, Thompson PA, Meltzer HY. Effects of clozapine on cognitive function in schizophrenia. j Clin. Psychiatry 55, 82–87 (1994).
- Green MF, Marshall BD, Wirshing WC et al. Does risperidone improve verbal working memory in treatment resistant schizophrenia? Am. j P9rhiatry154,799–804 (1997).
- Keefe R, Silva S et al The effects of atypical antipsychotic drugs on neurocognitive impairment in schizophrenia: a review and meta-analysis. Schiz. Bull. 25,201–222 (1999).
- Purdon SE, Jones BD, Stip E et al, for the Canadian Collaborative Group for Research on Cognition in Schizophrenia Neuropsychological change in early phase schizophrenia during 12 months of treatment with olanzapine, risperidone or haloperidol. Azrh. Gen. PsychMtry57, 249–258 (2000).
- Harvey PD, Keefe RSE. Studies of cognitive change in patients with schizophrenia following novel antipsychotic treatmentAm. Psychiatry158,176–184 (2001).
- Tollefson GD, Sanger TM. Negative symptoms: a path analytic approach to a double-blind, placebo- and haloperidol-controlled clinical trial with olanzapine. Arn. Psychiatry154, 466–474 (1997).
- Kopelowicz A, Zarate R, Tripodis K et al Differential efficacy of olanzapine for deficit and nondeficit negative symptoms in schizophrenia. Am. j Psychiatry 157,987–993 (2000).
- Essock SM, Hargreaves WA, Covell NH et al Antipsychotics in research and clinical settings: Clozapine's effectiveness for patients in state hospitals: Results from a randomized trial. P9rhopharm. Bull. 32, 683–697 (1996).
- Rosenheck R, Cramer J, Xu W et al A comparison of clozapine and haloperidol in hospitalized patients with refractory schizophrenia. Department of Veterans Affairs Co-operative Study on clozapine in refractory schizophrenia. N Engl. I Med. 337,809–815 (1997).
- Tamminga CA, Thaker GK, Moran M et al. Clozapine in tardive dyskinesia: observations from human and animal model studies. j Clin. Fiychiatry55(Suppl. B), 102–106 (1994).
- Tollefson GD, Beasley CM, Tamura RN et al. Blind, controlled, long-term study of the comparative incidence of treatment-emergent tardive dyskinesia with olanzapine or haloperidol. Am. J. Psychiatry 154,1248–1254 (1997).
- Beasley CM, Dellva MA, Tamura RN. Randomised double-blind comparison of the incidence of tardive dyskinesia in patients with schizophrenia during long-term treatment with olanzapine or haloperidol. BE Bychiatry174, 23–30 (1999).
- Glazer WM. Expected incidence of tardive dyskinesia associated with atypical antipsychotics. j Clin. P9rhiatry61\(Suppl. 4), 21–26 (2000).
- Glazer WM, Morganstern H, Puitz JA et al Incidence of persistent tardive dyskinesia is lower with quetiapine treatment than with typical antipsychotics in patients with schizophrenia or schizoaffective disorders. Schiz. Res. 41, 206–207 (2000).
- Marder SR, Essock SM, Miller AL et al The Mount Sinai conference on the pharmacotherapy of schizophrenia. Schiz. Bull. (In Press).
- ••Expert consensus of evidence-basedtreatment recommendations in the pharrnacotherapy of schizophrenia, focusing on areas where there have been disagreements among experts or substantial variations in clinical practice.
- Rosenheck R, Cramer J, Allen E et al Cost- effectiveness of clozapine in patients with high and low levels of hospital use. Arch. Gen. Psychiatry 56, 565–572 (1999).
- •Cost-effectiveness study of dozapine in the US Veterans Affairs Healthcare System.
- Essock SM, Hargreaves WA, Dohm F et al Clozapine eligibility among state hospital patients. Schiz Bul122,15–25 (1996).
- Azorin J, Spiegel R, Remington G et al A double-blind comparative study of clozapine and risperidone in the management of severe chronic schizophrenia. Am. J. Psychiatry 158,1305–1313 (2001).
- Reid WH, Mason M, Hogan T Suicide prevention effects associated with clozapine therapy in schizophrenia and schizoaffective disorder. P9rhiatr Serv. 49, 1029–1033 (1998).
- Walker AM, Lanza LL, Arellano F et al. Mortality in current and former users of clozapine. Epidemiology8, 671–677 (1997).
- Sernyak MJ, Desai R, Stolar M et al Impact of clozapine on completed suicide. Am.Fiychiatry 158,931–937 (2001).
- Allison DB, Mentore JL, Heo M et al Antipsychotic-induced weight gain: a comprehensive research synthesis. Am. J. Psychiatry 156,1686–1696 (1999).
- Henderson DC, Cagliero E, Gray C et al. Clozapine, diabetes mellitus, weight gain and lipid abnormalities: a five-year naturalistic study. Am. J. PFchiatry157, 975–981 (2000).
- Conley RR, Mahmoud R. A randomized double-blind study of risperidone and olanzapine in the treatment of schizophrenia or schizoaffective disorder. AIR J. PFthiatry158, 765–774 (2001).
- Wirshing DA, Spellberg BJ, Erhart SM et al. Novel antipsychotics and new onset diabetes. Biol. Psychiatry 44, 778–783 (1998).
- Gaulin BD, Markowitz JS, Caley CF et al Clozapine-associated elevation in serum triglycerides. Am.j Psychiatry 156,1270–1272 (1999).
- Kingsbury SJ, Fayek M, Trufasiu D et al The apparent effects of ziprasidone on plasma lipids and glucose. J. Clin. Psychiatry 62,347–349 (2001).
- Olfson M, Mechanic D, Hansell S et al Predicting medication noncompliance after hospital discharge among patients with schizophrenia. P9rhiatr Serv. 51,216-222 (2000).
- Wahlbeck K, Tuunainen A, Ahokas A et al Dropout rates in randomised antipsychotic drug trials. P9rhophatmacology (er1)155, 230–233 (2001).
- Geddes J, Freemantle N, Harrison P et al Atypical antipsychotics in the treatment of schizophrenia: systematic overview and meta-regression analysis. BE Med. 1. 321, 1371–1376 (2000).
- Essock SM, Frisman LK, Covell NH. The economics of the treatment of schizophrenia. In: Neuropsychopharmacology: The Fifth Generation of Proqirss. Davis KL, Charney D, Coyle J, Nemeroff C (Eds.), Lippincott Williams & Wilkins (In Press).
- ••Review of schizophrenia cost and cost-effectiveness studies, with discussion of methodologic issues.
- Covell NH. Personal communication (2001).
- Henderson DC, Goff DC. Risperidone as an adjunct to clozapine therapy in chronic schizophrenics. I Clin. Psychiatry 57,395–397 (1996).
- Mowerman S, Sins SG. Adjunctive loxapine in a clozapine-resistant cohort of schizophrenic patients. Ann. Clin. P9rhiatry8,193–197 (1996).
- Friedman J, Ault K, Powchik P. Pimozide augmentation for the treatment of schizophrenic patients who are partial responders to clozapine.Rychiatry42,522–523 (1997).
- Shiloh R, Zemishlany Z, Aizenberg D et al Sulpiride augmentation in people with schizophrenia partially responsive to clozapine. A double-blind, placebo-controlled study. Br: Psychiatry172,449–450 (1997).
- Gupta S, Sonnenbery SJ, Frank B. Olanzapine augmentation of clozapine. Ann. Clin. Bychiatry10, 113–115 (1998).
- Morera AL, Barreiro P, Cano-Munoz JL. Risperidone and clozapine combination for the treatment of refractory schizophrenia. Acta PTchiatr. Scand. 99,305–306 (1999).
- Raskin S, Katz G, Zislin Z et al Clozapine and risperidone: combination/ augmentation treatment of refractory schizophrenia: a preliminary observation. Acta PTchiatr. Scand. 101,334–336 (2000).
- Raskin S, Durst R, Katz G et al. Olanzapine and sulpiride: a preliminary study of combination/augmentation in patients with treatment-resistant schizophrenia. J. Gun. Bychopharmacol. 20,500–503 (2000).
- Lerner V, Chudakova B, Kravets S, Polyakova I. Combined use of risperidone and olanzapine in the treatment of patients with refractory schizophrenia: a preliminary report. Gun. Neuropharm. 23,284–286 (2000).
- de Groot IW Heck AH, van Harten PH. Addition of risperidone to clozapine therapy in chronically psychotic in-patients. j Gun. Bychiatry62, 129–130 (2001).
- Hogan ME New futures for mental healthcare: the case of Ohio. Health Aff MIlwood)11, 69–83 (1992).
- Hogan ME Public-sector mental healthcare: new challenges. Health Aff (MiIlwood)18,106–111 (1999).
- Glazer W, Dickson R. Pharmacoeconomics and resource allocation: lessons from North America. In: Schizophrenia and Mood Disarlers: the new drug therapies in clinical practice. Buckley PF, Waddington (eds), Boston, MA, USA 330–344 (2000).
- ••Discussion of economics of schizophreniatreatment, fragmentation of funding streams in North America, and risk-sharing as a potential solution.
- Rice DR Economic burden of mental disorders in the United States. TEN1, 40-44(1999).
- Greer S, Greenbaum R Fear-based advertising and the increase in psychiatric hospitalization of adolescents. Hasp. Comm. fisychtry 43, 1038–1039 (1992).
- Lutz S. NME to pay fine of $379 million. Mod. Healthcare 24(27), 2–13 (1994).
- Lutz S. More fraud cases seen. Mod. Healthcare 24 (43), 24 (1994) .
- Reid WH, Mason M, Toprac M. Savings in hospital bed-days related to treatment with clozapine. Hasp. Comm. Bychiatry45, 261–264 (1994).
- Breier A, Buchanan RVV, Irish D et al Clozapine treatment of out-patients with schizophrenia: outcome and long-term response patterns. Hasp. Comm. Psychiatry 44,1145–1149 (1993).
- Addington DE, Jones B, Bloom D et al Reduction of hospital days in chronic schizophrenic patients treated with risperidone: a retrospective study. Gun. Ther: 15,917–925 (1993).
- Conley RR, Love RC, Kelly DL et al. Rehospitalization rates of patients recently discharged on a regimen of risperidone or clozapine. Aim j Psychiatry 156,863–868 (1999).
- Essock SM, Frisman LK, Covell NH et al. Cost-effectiveness of clozapine compared with conventional antipsychotic medications for patients in state hospitals. Arch. Gen. Psychiatry 57,987–994 (2000).
- •Cost-effectiveness of clozapine in various outcome domains; demonstrates complexity of cost-effectiveness analyses.
- Essock SM, Goldman IIf I. States' embrace of managed mental healthcare. Health Aff (Millwood)14,34–44 (1995).
- Essock SM. Management approaches for mental health program report cards. Comm. Mental Healthj 34,107–109 (1998).
- Hargreaves WA, Shumway M, Hu T, Cuffel B. Cost-Outcome Methods for Mental Health San Diego, CA, USA. (1998).
- •General reference for carrying out cost-effectiveness studies.
Websites
- HCFA website: http://medicare.hcfa.gov/ drugs/drug5.htm
- Kapur S. Polypharmacy-in-a-pill: a scientific advance or are we making a virtue of our necessities? Medscape Mental Health (2001) 6: http://psychiatry.medscape.com/ Home/Topics/psychiatry/psychiatry.html
- Texas Medication Algorithm Project website: www.mhmr.state.tx.us/ centraloffice/medicaldirector/tmap.html
- •Contains medication algorithm for schizophrenia treatment and information about implementation.